Understanding Adnexal Masses

Understanding Adnexal Masses
An adnexal mass—affecting the ovary, fallopian tube, or surrounding tissues—is a common gynecologic finding that can occur at any age. While most are benign, proper evaluation and management are essential for optimal outcomes and preservation of reproductive health.
prof Mykhailo Medvediev
Department of Obstetrics and Gynecology
What Are Adnexal Masses?
Definition
Adnexal masses are solid or cystic growths in the ovary, fallopian tube, or surrounding connective tissues. They represent one of the most frequent gynecologic concerns, with varied causes ranging from normal physiologic processes to pathologic conditions.
Prevalence
Ovarian masses are identified in approximately 8-35% of premenopausal patients and 3-17% of postmenopausal patients, making them a significant clinical consideration across all age groups.
Types of Adnexal Masses
Physiologic Cysts
Normal follicular cysts and corpus luteum cysts arising from ovulation—most common in premenopausal patients and typically resolve spontaneously.
Benign Neoplasms
Including mature teratomas (dermoid cysts), cystadenomas, and endometriomas—require evaluation but are non-cancerous.
Malignant Tumors
Ovarian, fallopian tube, or peritoneal cancers—require prompt diagnosis and specialized treatment by gynecologic oncologists.
Age-Related Considerations
The likelihood and type of adnexal masses vary significantly by age and reproductive status, influencing both diagnostic approach and treatment decisions.
Pediatric and Adolescent Patients
Key Facts
Most masses are physiologic cysts
Ovarian neoplasms account for ~1% of tumors
Germ cell tumors most common malignancy
Fewer than 5% of ovarian cancers occur in this age group
Between menarche and age 18, ovulatory dysfunction is common due to an immature hypothalamic-pituitary-ovarian axis. Adolescent ovaries may contain multiple follicles in different developmental stages, including unilocular and hemorrhagic cysts that typically resolve spontaneously.
While ovarian neoplasms are rare, germ cell tumors represent the most common histology when malignancy does occur, comprising 50-67% of ovarian neoplasms in patients up to 18 years.
Premenopausal Patients
Hormone-Related Masses
Functional cysts, corpus luteal cysts, endometriomas, and leiomyomas are stimulated by reproductive hormones and found almost exclusively in this age group.
Benign Neoplasms
Common benign masses include mature teratomas and cystadenomas, which typically require surgical evaluation but have excellent prognoses.
Malignancy Risk
While ovarian cancers increase with age, germ cell tumors peak between ages 10-30, representing 70% of ovarian neoplasms in this demographic.
Postmenopausal Patients
Most adnexal cysts in postmenopausal patients are benign, but the incidence of ovarian cancer increases with advancing age, requiring heightened vigilance in evaluation.
Simple Cysts
Common findings representing persistent physiologic cysts, benign cystadenomas, or paraovarian cysts. Risk of malignancy in simple cysts is very low.
Epithelial Neoplasms
Benign or borderline ovarian epithelial neoplasms may occur, including serous or mucinous cystadenomas requiring surgical evaluation.
Malignancy
Epithelial carcinoma is the most common histologic type, accounting for 90% of ovarian, fallopian tube, and peritoneal cancers.
Clinical Presentation
Patients with adnexal masses may be asymptomatic or present with various symptoms. Understanding these presentations guides appropriate evaluation and management.
Common Symptoms
Pelvic Pain or Pressure
Most common symptom, often unilateral, varying in severity from dull ache to sharp pain, constant or intermittent.
Abdominal Symptoms
Fullness, bloating, nausea, vomiting, constipation, or early satiety may indicate larger masses or complications.
Urinary Changes
Difficult or frequent urination can occur when masses compress the bladder or urinary tract.
Menstrual Changes
Dysmenorrhea, dyspareunia, or abnormal uterine bleeding may accompany certain mass types, particularly endometriomas.
When to Seek Immediate Care
Emergency Situations
Patients with acute and/or severe pain or hemodynamic instability should be evaluated immediately in the emergency department. These symptoms may indicate ovarian torsion, ruptured cyst with hemorrhage, or ectopic pregnancy—all requiring urgent intervention.
Adnexal masses requiring prompt intervention include ectopic pregnancy, ovarian torsion, tubo-ovarian abscess, and ruptured hemorrhagic cysts causing hemodynamic instability. These conditions can cause serious morbidity and potential loss of ovarian function if not addressed quickly.
Diagnostic Evaluation
Comprehensive evaluation combines clinical assessment, imaging studies, and laboratory tests to characterize adnexal masses and guide management decisions.
Initial Assessment
Medical History
Menstrual history and last menstrual period
Pain characteristics and severity
Presence or absence of fever
Sexual history and fertility concerns
Risk factors for ovarian cancer
Family history of gynecologic cancers
Physical Examination
Pelvic examination assesses mass size, consistency, and mobility when palpable. Small masses may be difficult to detect due to deep anatomic location, while very large masses can extend beyond the pelvis.
Important findings include pain with palpation, abdominal distention, ascites, irregular or fixed masses, and posterior cul-de-sac nodularity—all suggesting potential malignancy or endometriosis.
Ultrasound Imaging
Transvaginal ultrasonography is the first-line imaging study for characterizing adnexal masses, offering detailed visualization of ovarian structures and surrounding tissues.
Primary Technique
Gray-scale ultrasound combined with color Doppler evaluation provides comprehensive assessment of mass size, location, composition, and blood flow patterns.
Diagnostic Performance
Ultrasound is highly effective at determining which masses are "almost certainly benign" versus those with "reasonable chance of malignancy," guiding appropriate management.
O-RADS Classification System
The American College of Radiology Ovarian-Adnexal Reporting and Data System (O-RADS) provides standardized risk stratification for adnexal masses based on ultrasound findings.
01
O-RADS 1: Normal Ovary
Includes follicles and corpus lutea ≤3 cm—physiologic findings requiring no intervention.
02
O-RADS 2: Almost Certainly Benign
Risk of malignancy <1%—includes typical hemorrhagic cysts, dermoids, endometriomas, and simple cysts.
03
O-RADS 3: Low Risk
Risk of malignancy 1 to <10%—may require surveillance or additional imaging for clarification.
04
O-RADS 4: Intermediate Risk
Risk of malignancy 10 to <50%—typically warrants surgical evaluation or oncology consultation.
05
O-RADS 5: High Risk
Risk of malignancy ≥50%—requires surgical intervention, preferably by gynecologic oncologist.
Laboratory Testing
Basic Tests
All patients require pregnancy test and complete blood count as part of initial evaluation.
Tumor Markers
Cancer antigen 125 (CA 125) is measured in all postmenopausal patients with adnexal masses. In premenopausal patients, CA 125 is measured only if ultrasound appearance raises sufficient suspicion of malignancy to warrant repeat ultrasound or surgical evaluation.
Other markers including HE4, CEA, and CA 19-9 may be useful in specific situations. Patients with symptoms of hormone excess may require additional testing for germ cell or sex cord-stromal tumors.
Management Strategies
Management of adnexal masses depends on risk stratification, patient age, symptoms, and reproductive goals, ranging from expectant observation to surgical intervention.
Management Approaches
The principal goals are determining whether masses are "almost certainly benign" or have "reasonable chance of malignancy," and identifying urgent conditions requiring prompt treatment. Management strategies are individualized based on these assessments.
Expectant Management
When masses are not suspicious for malignancy and have no other indications for surgery or surveillance, no further follow-up is needed. This approach is appropriate for:
Simple Cysts
Thin-walled, unilocular cysts <5 cm in premenopausal or <3 cm in postmenopausal patients are considered normal findings.
Physiologic Cysts
Follicular cysts and corpus luteum cysts in premenopausal patients typically resolve spontaneously within weeks to months.
Classic Benign Lesions
Characteristic dermoids, endometriomas, and hydrosalpinges <10 cm without concerning features may be observed if asymptomatic.
Surveillance Protocols
Surveillance is appropriate when suspicion of malignancy is low but not completely excluded, typically including serial ultrasounds and tumor marker measurements.
Intermediate-Risk Masses (O-RADS 4)
Postmenopausal: Repeat transvaginal ultrasound and CA 125 at 6 weeks, 12 weeks, then every 3-6 months for one year, with final assessment after one additional year.
Premenopausal: Repeat ultrasound at 6 weeks, 3 months, and 6 months, with final assessment after one additional year. CA 125 repeated only if initially elevated.
Low-Risk Masses (O-RADS 3)
For most patients with low-risk masses and no surgical indications, repeat transvaginal ultrasound at 3 months and again at 6 months provides adequate surveillance.
Studies show that masses stable for one year have very low risk of malignancy, with no cancers diagnosed after one year of stability on ultrasound.
When to Stop Surveillance
Proceed with Surgery If:
Mass develops high-risk features of malignancy
Mass is increasing in size or reaches ≥10 cm
Tumor markers become elevated or trend upward
Patient develops persistent symptoms
New findings suggest metastatic disease
If masses remain unchanged or decrease in size with normal tumor markers, surveillance continues until the planned stopping point. If masses resolve completely, surveillance is discontinued.
Surgical Management
Surgery is performed when there is high risk of malignancy, histologic diagnosis is desired, or patients have persistent pain or symptoms unresponsive to conservative management.
Indications for Surgery
High-Risk Masses
O-RADS 5 masses or imaging findings suggestive of metastatic disease require surgical intervention for diagnosis and treatment.
Postmenopausal Criteria
Elevated CA 125 >35 units/mL, mass ≥10 cm, or intermediate-risk mass with symptoms/risk factors for ovarian cancer.
Premenopausal Criteria
Intermediate-risk mass with CA 125 >200 units/mL, or suspected germ cell or sex cord-stromal tumor.
Oophorectomy vs. Cystectomy
Ovarian Preservation
When surgery is indicated for benign disease, preservation of as much ovarian cortex as possible through cystectomy is generally preferable to complete oophorectomy.
Studies support preserving ovarian function up to age 65, showing lower all-cause mortality compared with elective oophorectomy. Even minimal remaining ovarian tissue can maintain hormonal function.
When Oophorectomy Is Indicated
Benign neoplasms not amenable to cystectomy
Ovarian malignancy requiring staging
Adnexal torsion with necrosis
Tubo-ovarian abscess unresponsive to antibiotics
Risk-reducing surgery for hereditary cancer syndromes
Surgical Approach: Open vs. Minimally Invasive
Most ovarian surgeries for benign disease are performed via minimally invasive surgery (MIS), utilized in almost 90% of cases in recent studies.
Minimally Invasive Surgery
Advantages include shorter recovery time, reduced hospital stay, lower cost, and less adhesion formation—particularly important for fertility preservation.
Open Laparotomy
May be more appropriate when dense adhesions present, ovary is very large, or high suspicion of malignancy requiring comprehensive staging.
Robotic-Assisted Surgery
Emerging approach offering enhanced visualization and precision, though operative duration may be slightly longer than conventional laparoscopy.
Benefits of Minimally Invasive Surgery
90%
MIS Utilization
Percentage of ovarian surgeries for benign disease performed via minimally invasive approach in recent US cohort studies.
50%
Faster Recovery
Reduction in recovery time compared to open laparotomy, allowing quicker return to normal activities.
0.04%
Unsuspected Cancer
Rate of finding unsuspected ovarian cancer during laparoscopic ovarian cyst surgery with appropriate patient selection.
Oophorectomy Procedure
Oophorectomy involves careful identification of anatomic structures, particularly the ureter, followed by systematic division and ligation of vascular pedicles.
The procedure begins with obtaining pelvic and abdominal washings for potential staging. The entire pelvis, abdomen, and retroperitoneum are inspected for lesions suspicious for carcinoma before proceeding with removal.
Ovarian Cystectomy Technique
Open Approach
An elliptical incision is made over thin ovarian cortex in the ovarian axis. The cyst wall is dissected from surrounding stroma using blunt or sharp dissection, with every attempt to remove the cyst intact.
After removal, the ovarian cortex may be left open if hemostasis is adequate, or reapproximated if needed. The cortex should not be trimmed as this removes viable ovarian tissue.
Laparoscopic Approach
After thorough inspection and adhesiolysis, the ovarian cortex is incised circumferentially around the cyst base. The cyst is separated from remaining ovary using blunt or sharp dissection.
Intact removal through a specimen bag is preferable. If cystotomy is needed, contents are aspirated under controlled conditions, the cavity irrigated, and the cyst wall carefully dissected from ovarian stroma.
Postoperative Considerations
Understanding potential complications and long-term outcomes helps optimize patient care and set appropriate expectations for recovery and future fertility.
Potential Complications
1
Ureteral Injury
Can occur with open or minimally invasive approaches when ureteral identification is performed incorrectly. Careful visualization is essential.
2
Spillage of Malignant Cells
Capsule rupture of ovarian tumor may worsen prognosis. Patients often receive chemotherapy unless tumor is well differentiated.
3
Bleeding and Infection
Standard surgical risks including hemorrhage, infection, and adhesion formation requiring appropriate perioperative management.
4
Conversion to Laparotomy
May be necessary if difficult dissection encountered, unexpected findings discovered, or complications arise during minimally invasive approach.
Ovarian Remnant Syndrome
Ovarian remnant syndrome (ORS) occurs when patients who underwent bilateral oophorectomy subsequently present with symptoms related to ovulatory function from inadvertently retained ovarian tissue.
Risk Factors
Dense adhesions from endometriosis or PID
Neoplastic disease
Increased pelvic vascularity
Intraoperative bleeding
Anatomic variation
Clinical Presentation
Typical patients present with cyclic pelvic pain and a mass, though pain may be persistent with acute flare-ups. Occasionally an asymptomatic mass is detected on examination or imaging.
Diagnosis is suggested by premenopausal FSH levels or normal estradiol after bilateral oophorectomy, though some patients have postmenopausal hormone levels. Ultrasound, CT, or MRI typically identify a pelvic mass.
Fertility After Unilateral Oophorectomy
Pregnancy rates following removal of one ovary vary widely in the literature, ranging from 42-88% in patients with ovarian cancer or tumors of low malignant potential who undergo conservative surgery.
90%
Ovarian Reserve
Patients with one ovary maintain similar quality of ovarian pool compared to those with two ovaries, though quantity may be reduced.
2.7
Fewer Follicles
Average reduction in follicles per cycle for patients with single ovary undergoing IVF, though pregnancy rates remain comparable.
For patients undergoing in vitro fertilization, data show those with a single ovary have lower quantity but similar quality of the ovarian pool. This effect likely varies with age, as younger patients have more follicles per ovary.
Special Populations
Certain patient populations require specialized considerations in the evaluation and management of adnexal masses.
Patients with Hereditary Cancer Syndromes
Increased Risk
Patients with BRCA1, BRCA2 mutations, or Lynch syndrome have significantly elevated lifetime risk of ovarian, fallopian tube, and peritoneal cancers.
These patients are managed differently than the general population, with lower threshold for surgical exploration and consideration of risk-reducing salpingo-oophorectomy.
Timing of Intervention
Risk-reducing surgery is typically recommended after completion of childbearing, usually between ages 35-40 for BRCA mutation carriers or 5-10 years before earliest family diagnosis.
Any adnexal mass in these patients warrants careful evaluation and often surgical management given elevated baseline cancer risk.
Pregnant Patients
Adnexal masses in pregnancy present unique diagnostic and management challenges, requiring careful balance between maternal and fetal safety.
Corpus Luteum
Early pregnancy always associated with corpus luteum cyst, typically <2.5 cm but occasionally larger and painful due to hemorrhage.
Luteoma
Non-neoplastic solid ovarian mass associated with pregnancy, sometimes mistaken for neoplasm, involutes spontaneously after delivery.
Decidualized Endometrioma
Endometriomas may become decidualized during pregnancy, raising suspicion of malignancy due to solid elements with flow.
Patients with Complete Androgen Insensitivity
Phenotypic females with Y chromosome in their karyotype have increased risk of gonadal malignancy and should undergo gonadectomy to avoid the 20-30% risk of malignant tumors arising in gonadal tissue.
Timing of Surgery
Gonadectomy is delayed until after pubertal development as it is rare to develop malignancy before age 20. The procedure can be safely performed using minimally invasive approach, with preservation of uterus and fallopian tubes to permit future childbearing using donor oocytes.
Specific Mass Types: Endometriomas
Endometriomas, or "chocolate cysts," are benign ovarian masses arising from ectopic growth of endometrial tissue, commonly associated with endometriosis.
Endometrioma Characteristics
Sonographic Features
Homogeneous "ground glass" low- to medium-level echoes
Unilocular or multilocular cystic mass
Small echogenic foci on inner cyst wall
Varying echogenicity in different locules
Absence of solid component
Clinical Presentation
Patients often experience dysmenorrhea, pelvic pain, or infertility. Endometriomas are frequently associated with endometriosis at other pelvic sites.
Up to 25% may have solid-appearing nodular component due to clot or focal endometrial tissue, which can be difficult to distinguish from neoplasm, particularly in postmenopausal patients.
Endometrioma Management
1
Expectant Management
Surveillance preferred when patient is asymptomatic and endometrioma is small (generally <5 cm).
2
Medical Therapy
Hormonal suppression may reduce symptoms but does not eliminate endometriomas or improve fertility outcomes.
3
Surgical Excision
Usual treatment if symptomatic, infertile, or increasing in size. Complete cyst removal important to prevent recurrence.
Surgical removal is the usual treatment if the patient is symptomatic, infertile, or the endometrioma is increasing in size. It is particularly important to remove all cyst wall when dealing with endometriomas to prevent recurrences and improve reproductive outcomes.
Specific Mass Types: Mature Teratomas
Mature cystic teratomas (dermoid cysts) are benign germ cell tumors and the most common ovarian neoplasm in the second and third decades of life.
Teratoma Characteristics
Mature teratomas can contain elements differentiated to all three germ cell layers: ectodermal (skin, hair follicles, sebaceous glands), mesodermal (muscle, urinary), and endodermal origin (lung, gastrointestinal).
Hyperechoic Nodule
Markedly hyperechoic nodule within mass, particularly with distal acoustic shadowing, is strong indicator of teratoma.
Fluid-Fluid Level
If echogenic fluid is nondependent, this is predictive of teratoma, though occurs in minority of cases with fluid levels.
Calcification
May be present and vary in size, but calcification alone is not sufficient criterion to diagnose dermoid.
Floating Globules
Uncommon appearance but seems to be predictive of teratoma when present on imaging.
Teratoma Management
Surgical Indications
Surgery (ovarian cystectomy) is indicated in most cases to make definitive diagnosis and avoid potential problems such as torsion or malignant transformation.
Although uncommon, mature teratomas can rupture, requiring urgent surgical intervention. Bilateral teratomas occur in 10-15% of patients.
Surgical Considerations
When dermoid cystectomy is performed, care should be taken to irrigate extensively after cystotomy. Persistence of teratoma fluid may cause chemical peritonitis.
Any mass with features of teratoma must be evaluated with color Doppler imaging, since identification of flow within suspected teratoma makes diagnosis unlikely and raises possibility of malignant teratoma.
Specific Mass Types: Hydrosalpinx
A hydrosalpinx occurs when fluid fills the fallopian tube, typically as result of scarring or "clubbing" of tubal fimbriae from untreated or undertreated pelvic inflammatory disease.
Hydrosalpinx Features and Management
Sonographic Appearance
Usually appears tubular in shape with incomplete or partial "septations" due to tube wall folded on itself, or very small nodules representing thickened endosalpingeal folds.
Diagnostic Features
Three-dimensional ultrasound using sectional planes useful to visually reconstruct hydrosalpinx. "Waist sign" (indentations along opposite walls) may help identify hydrosalpinx.
Management
Asymptomatic hydrosalpinx generally does not need removal or follow-up. Exception is patients undergoing IVF, where pregnancy rates improve after surgical removal.
Hydrosalpinx and Fertility
After acute pelvic inflammatory disease resolves, a hydrosalpinx may remain. Tubal function is often compromised, potentially contributing to infertility.
Impact on IVF Outcomes
For symptomatic patients, other etiologies of chronic pelvic pain should be excluded before salpingectomy is performed. However, for patients undergoing in vitro fertilization, pregnancy rates can be improved after surgical removal of the hydrosalpinx.
Referral to Gynecologic Oncologist
Referral to a gynecologic oncologist is advised for masses suspicious for ovarian, fallopian tube, or peritoneal cancer, as outcomes are superior when procedures are performed by specialists.
Benefits of Specialist Care
6-9
Survival Benefit (Months)
Median survival benefit for patients with advanced ovarian cancer when operated on by gynecologic oncologist versus other surgeons.
93%
Optimal Staging
Percentage of early-stage disease cases where gynecologic oncologists performed optimal staging compared to general surgeons.
100%
Comprehensive Care
Gynecologic oncologists provide complete surgical staging, cytoreduction, and coordinated multidisciplinary treatment planning.
Referral Criteria
The American College of Obstetricians and Gynecologists and Society of Gynecologic Oncology published joint guidelines about referral of patients with adnexal masses to gynecologic oncologists.
Premenopausal Patients
Very elevated CA 125 level, ascites, evidence of abdominal or distant metastases, or family history of breast or ovarian cancer.
Postmenopausal Patients
Elevated CA 125 level, ascites, nodular or fixed pelvic mass, evidence of abdominal or distant metastases, or family history of breast or ovarian cancer.
Imaging Findings
High-risk features on ultrasound (O-RADS 5), complex mass with solid components and blood flow, or findings suggestive of metastatic disease.
Prevention and Risk Reduction
While most adnexal masses cannot be prevented, certain strategies can reduce risk of complications and improve early detection of concerning masses.
Reducing Complications
Regular Screening
Annual pelvic examinations allow early detection of adnexal masses, though routine ultrasound screening is not recommended for average-risk patients.
Patients with hereditary cancer syndromes may benefit from enhanced surveillance protocols including transvaginal ultrasound and CA 125 measurements.
Prompt Evaluation of Symptoms
Seeking medical attention for persistent pelvic pain, bloating, urinary symptoms, or abnormal bleeding allows timely diagnosis and management.
Awareness of ovarian cancer symptoms is particularly important for postmenopausal patients and those with family history of gynecologic cancers.
Oral Contraceptives and Ovarian Cysts
Combined estrogen-progestin oral contraceptives (COCs) inhibit ovulation and prevent formation of new physiologic ovarian cysts, though they do not decrease size of existing cysts.
01
Mechanism
COCs suppress gonadotropin release, preventing follicular development and ovulation, thereby reducing formation of functional cysts.
02
Effectiveness
Patients using COCs with ≤35 mcg ethinyl estradiol develop fewer follicular cysts than those not using hormonal contraception.
03
Clinical Use
Provides time for existing cysts to resolve while reducing chances of new symptomatic cyst formation in patients with recurrent painful cysts.
Patient Education and Counseling
Comprehensive patient education about adnexal masses, treatment options, and expected outcomes is essential for informed decision-making and optimal care.
Key Discussion Points
Nature of Mass
Explain whether mass is likely benign or requires further evaluation, using O-RADS classification to communicate risk level clearly.
Management Options
Discuss expectant management, surveillance, or surgical options, including benefits and risks of each approach for patient's specific situation.
Fertility Considerations
Address impact on future fertility, particularly for premenopausal patients, and discuss ovarian preservation strategies when appropriate.
Follow-Up Plans
Establish clear surveillance schedules or surgical timelines, with specific criteria for when to seek urgent evaluation.
Shared Decision-Making
Patient Preferences
Understanding patient values, fertility goals, and tolerance for uncertainty guides individualized treatment planning.
Informed Consent
Thorough counseling about surgical risks, including potential for finding unexpected malignancy, conversion to laparotomy, and impact on ovarian function, ensures patients can make informed decisions.
Discussion should include alternatives to surgery when appropriate, expected recovery time, and long-term implications of different management strategies.
Emerging Technologies and Research
Ongoing research continues to refine diagnostic approaches and treatment strategies for adnexal masses, improving outcomes and reducing unnecessary interventions.
Advanced Imaging Techniques
Magnetic Resonance Imaging
MRI provides superior tissue characterization for indeterminate masses, helping differentiate benign from malignant lesions when ultrasound is inconclusive.
Three-Dimensional Ultrasound
3D imaging techniques improve visualization of complex anatomic relationships, particularly useful for diagnosing hydrosalpinx and peritoneal inclusion cysts.
Contrast-Enhanced Ultrasound
CEUS uses microbubbles to evaluate mass perfusion patterns, showing promise in distinguishing benign from malignant lesions, though not yet widely adopted.
Biomarker Development
Research continues to identify novel biomarkers and multimodal tests to improve preoperative risk stratification and reduce unnecessary surgeries for benign disease.
HE4 (Human Epididymis Protein 4)
Complementary marker to CA 125, particularly useful in premenopausal patients where CA 125 has limited specificity.
ROMA Score
Risk of Ovarian Malignancy Algorithm combines CA 125, HE4, and menopausal status to calculate malignancy risk.
OVA1 and Overa
Multi-marker panels measuring multiple proteins to assess malignancy risk, FDA-approved for clinical use.
Surgical Innovations
Single-Port Laparoscopy
Laparoendoscopic single-site surgery (LESS) offers improved cosmetic results and potentially reduced postoperative pain compared to conventional laparoscopy.
Randomized trials show similar operative duration and complication rates to conventional laparoscopy for oophorectomy and ovarian cystectomy.
Enhanced Recovery Protocols
Implementation of enhanced recovery after surgery (ERAS) pathways reduces hospital stay, opioid use, and time to return to normal activities.
Protocols include optimized pain management, early mobilization, and standardized perioperative care to improve patient outcomes.
Long-Term Follow-Up
Appropriate long-term monitoring after treatment of adnexal masses ensures early detection of recurrence and addresses ongoing health concerns.
Post-Treatment Surveillance
1
Immediate Post-Op
Pathology review confirms diagnosis. If malignancy found, staging completed and oncology referral made for treatment planning.
2
3-6 Months
Follow-up examination and imaging if indicated. Assessment of symptom resolution and surgical site healing.
3
Annual
Routine gynecologic examination. Additional surveillance based on pathology results and individual risk factors.
Monitoring for Recurrence
Benign Disease
After treatment of benign masses, routine surveillance typically includes annual pelvic examinations. Additional imaging is performed only if symptoms develop or examination findings are concerning.
Patients with endometriomas may require ongoing medical management to prevent recurrence and manage associated endometriosis symptoms.
Borderline or Malignant Tumors
More intensive surveillance protocols include regular physical examinations, tumor marker measurements, and periodic imaging studies.
Frequency and duration of surveillance depend on tumor type, stage, and treatment received, typically coordinated by gynecologic oncology team.
Quality of Life Considerations
Treatment of adnexal masses can impact multiple aspects of patients' lives, from physical recovery to emotional well-being and reproductive health.
Physical Recovery
Pain Management
Multimodal analgesia strategies minimize opioid use while providing effective pain control during recovery period.
Return to Activities
Most patients resume normal activities within 2-6 weeks depending on surgical approach, with faster recovery after minimally invasive procedures.
Sexual Function
Counseling about resuming sexual activity and addressing any concerns about changes in sexual function or body image.
Emotional and Psychological Support
Diagnosis and treatment of adnexal masses can cause significant anxiety, particularly when malignancy is a concern or fertility is affected.
Coping with Uncertainty
Patients awaiting pathology results or undergoing surveillance may experience considerable stress. Providing clear information and support resources helps manage anxiety.
Support groups and counseling services can be valuable for patients dealing with cancer diagnosis or fertility concerns.
Fertility Counseling
Premenopausal patients facing surgery should receive comprehensive fertility counseling, including discussion of ovarian preservation strategies and reproductive options.
Referral to reproductive endocrinology specialists may be appropriate for patients with fertility concerns or those requiring fertility preservation.
Key Takeaways for Healthcare Providers
Optimal management of adnexal masses requires systematic evaluation, appropriate risk stratification, and individualized treatment planning based on patient characteristics and mass features.
Summary: Best Practices in Adnexal Mass Management
Comprehensive Evaluation
Combine clinical assessment, transvaginal ultrasound, and selective use of tumor markers to characterize masses and determine malignancy risk using standardized classification systems like O-RADS.
Individualized Management
Tailor approach based on patient age, symptoms, reproductive goals, and mass characteristics. Consider expectant management, surveillance, or surgery as appropriate for each clinical scenario.
Ovarian Preservation
When surgery is indicated for benign disease, preserve as much ovarian cortex as possible through cystectomy rather than oophorectomy, particularly in patients up to age 65.
Minimally Invasive Approach
Utilize minimally invasive surgery when appropriate, offering benefits of faster recovery, reduced complications, and lower cost compared to open laparotomy.
Timely Referral
Refer patients with masses suspicious for malignancy to gynecologic oncologists, as specialist care improves staging, treatment outcomes, and overall survival.
Patient-Centered Care
Engage patients in shared decision-making, provide comprehensive education about diagnosis and treatment options, and address fertility concerns and quality of life throughout the care continuum.
By following evidence-based guidelines and maintaining a patient-centered approach, healthcare providers can optimize outcomes for patients with adnexal masses while minimizing unnecessary interventions and preserving reproductive health when possible.